ORMP Oramed Pharmaceuticals Inc.
USHealthcareAs of 2026-07-08 16:00
Why ORMP matters now
Oramed Pharmaceuticals Inc. (ORMP) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.29 with -0.23% on the session and $175.6M in market capitalization; recent performance reads 1-month -10.39% and YTD +36.14%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $38.3M, and EPS of $0.91. Investors can compare that operating picture with valuation signals such as P/E 1.89 and FCF yield -5.5%.
The latest indexable market news headline is "Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet" from GuruFocus.
Additional event context on this page matters because analyst consensus is available with a median target of $—; recent insider activity includes Kidron Miriam filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
1.89
PEG
0.00
P/B
0.66
P/S
0.00
EV/EBITDA
1.86
DCF Value
$1.18
FCF Yield
-5.5%
Div Yield
6.4%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
55.3%
ROA
40.9%
ROIC
-4.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $38.3M | $0.91 |
| Q4 2025 | $0.00 | $10.0M | $0.23 |
| FY 2025 | $2.0M | $64.0M | $1.50 |
| Q3 2025 | $0.00 | $48.4M | $1.13 |
Analyst Ratings
Consensus
—
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.24
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.